Leerink Partners analyst Mani Foroohar has maintained their bullish stance on IONS stock, giving a Buy rating on February 20.
Mani Foroohar has given his Buy rating due to a combination of factors that indicate strong future prospects for Ionis Pharmaceuticals. The company’s fiscal year 2025 guidance suggests robust revenue growth surpassing $600 million and an operational strategy that anticipates a non-GAAP operating loss of less than $495 million, while maintaining a healthy cash reserve of approximately $1.7 billion by year-end.
The ongoing launch of Tryngolza for familial chylomicronemia syndrome and the positive momentum from Wainua, which has seen international launches and favorable recommendations from regulatory bodies, further bolster the growth potential. Additionally, significant upcoming pipeline catalysts, including the expected data from Ph3 studies of olezarsen and the initiation of Ph3 studies for ION582, contribute to a promising outlook. These elements combined with strong royalty streams from established products like Spinraza underpin the positive assessment.
According to TipRanks, Foroohar is an analyst with an average return of -10.7% and a 38.55% success rate. Foroohar covers the Healthcare sector, focusing on stocks such as Moderna, Alnylam Pharma, and BridgeBio Pharma.
In another report released on February 20, Raymond James also maintained a Buy rating on the stock with a $60.00 price target.